Our results are among the first to provide a mechanistic explanation for these differences with respect to variations in cytokines and substance P. This variability in the pathobiology of our transgenic models of pain is consistent with the heterogeneity seen clinically in SCD and cancer patients34. Here, TAC1 is linked to cancer.